UK markets close in 5 hours 25 minutes

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
74.89+1.13 (+1.53%)
At close: 04:00PM EDT
74.84 -0.05 (-0.07%)
After hours: 06:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close73.76
Open74.03
Bid74.77 x 100
Ask75.04 x 100
Day's range73.28 - 76.39
52-week range55.02 - 98.40
Volume448,361
Avg. volume726,011
Market cap3.557B
Beta (5Y monthly)1.10
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Axsome Therapeutics Recognizes May as Mental Health Awareness Month

    NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today is joining the global community of mental health advocates, including Mental Health America, during May’s Mental Health Month to raise awareness of the importance of mental health as a key element of overall health. Axsome is committed to the millions of individuals living wit

  • GlobeNewswire

    Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting

    AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting effects of solriamfetol NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced presentations highlighting its innovative p

  • GlobeNewswire

    Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

    NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets. Axsome’s management team will host a conference call at 8:00 a.m. Eastern Time on May 6, 2024, to discuss these results and